User: Guest  Login
Title:

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial.

Document type:
Article; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
Author(s):
Palace, Jacqueline; Wingerchuk, Dean M; Fujihara, Kazuo; Berthele, Achim; Oreja-Guevara, Celia; Kim, Ho Jin; Nakashima, Ichiro; Levy, Michael; Terzi, Murat; Totolyan, Natalia; Viswanathan, Shanthi; Wang, Kai-Chen; Pace, Amy; Yountz, Marcus; Miller, Larisa; Armstrong, Róisín; Pittock, Sean
Abstract:
BACKGROUND: Antibodies to the aquaporin-4 (AQP4) water channel in neuromyelitis optica spectrum disorder (NMOSD) are reported to trigger the complement cascade, which is implicated in astrocyte damage and subsequent neuronal injury. The PREVENT study demonstrated that the terminal complement inhibitor eculizumab reduces adjudicated relapse risk in patients with anti-AQP4 immunoglobulin G-positive (AQP4+) NMOSD. The objective of this analysis was to evaluate the efficacy of eculizumab in reducing...     »
Journal title abbreviation:
Mult Scler Relat Disord
Year:
2021
Journal volume:
47
Fulltext / DOI:
doi:10.1016/j.msard.2020.102641
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/33310418
Print-ISSN:
2211-0348
TUM Institution:
Neurologische Klinik und Poliklinik
 BibTeX